Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
- Conditions
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT00577278
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Effects of Exercise in Combination With Epoetin Alfa
- Conditions
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 120
- Registration Number
- NCT00577096
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- Drug: cyclophosphamideDrug: cyclosporineDrug: fludarabine phosphateDrug: gemcitabine hydrochlorideDrug: ifosfamideDrug: mechlorethamine hydrochlorideDrug: melphalanDrug: methotrexateDrug: mycophenolate mofetilDrug: prednisoneDrug: procarbazine hydrochlorideDrug: vincristine sulfateDrug: vinorelbine tartrateProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: total-body irradiation
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00574496
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideRadiation: External Beam Radiation TherapyBiological: FilgrastimDrug: IsotretinoinOther: Laboratory Biomarker AnalysisDrug: MelphalanProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyDrug: Topotecan HydrochlorideDrug: ThiotepaDrug: Vincristine Sulfate Liposome
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 665
- Registration Number
- NCT00567567
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2023-05-26
- Target Recruit Count
- 26
- Registration Number
- NCT00566098
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT00566696
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Duke University
- Target Recruit Count
- 20
- Registration Number
- NCT00565968
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning
- Conditions
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT00564200
- Locations
- 🇪🇸
H. de Jerez, Jerez de la Frontera, Spain
🇪🇸Instituto Catalán de Oncología, Barcelona, Spain
🇪🇸H. 12 de Octubre, Madrid, Spain
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2007-11-09
- Target Recruit Count
- 94
- Registration Number
- NCT00556127
- Locations
- 🇮🇹
Centro Trapianti Midollo Osseo, P.O. Businco, Cagliari, Italy
🇮🇹Ospedale S. Gerardo, Monza, Italy
🇮🇹Osp. maggiore della Carità, Novara, Italy
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 402
- Registration Number
- NCT00551928
- Locations
- 🇮🇹
Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.